 | • レポートコード：MRC2301F0082 • 出版社/出版日：Transparency Market Research / 2022年10月6日 • レポート形態：英文、PDF、166ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥869,250 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,319,250 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,769,250 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| トランスペアレンシー・マーケット・リサーチ社の当調査資料では、世界の疼痛管理治療市場について総合的に調査・分析を行い、序論、仮定・調査手法、市場概要、主要インサイト、治療薬別（抗けいれん薬、抗うつ薬、麻酔薬、非ステロイド性抗炎症薬（NSAIDS）、その他）分析、疾患別（神経障害性疼痛、線維筋痛症、関節痛、慢性腰痛）分析、投与経路別（経口、非経口、その他）分析、流通チャネル別（小売薬局、オンライン薬局、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東/アフリカ）分析、競争状況、企業情報などの項目を掲載しています。なお、当市場の主要企業には、Abbott、AstraZeneca plc、Pfizer, Inc.、Depomed, Inc.、Endo International plc、GlaxoSmithKline plc、Johnson & Johnson、Mallinckrodt Pharmaceuticals、Merck & Co., Inc.、Novartis AGなどが含まれています。 ・序論 ・仮定・調査手法 ・市場概要 ・主要インサイト ・世界の疼痛管理治療市場規模：治療薬別 - 抗けいれん薬の市場規模 - 抗うつ薬の市場規模 - 麻酔薬の市場規模 - 非ステロイド性抗炎症薬（NSAIDS）の市場規模 - その他治療薬の市場規模 ・世界の疼痛管理治療市場規模：疾患別 - 神経障害性疼痛における市場規模 - 線維筋痛症における市場規模 - 関節痛における市場規模 - 慢性腰痛における市場規模 ・世界の疼痛管理治療市場規模：投与経路別 - 経口投与の市場規模 - 非経口投与の市場規模 - その他投与経路の市場規模 ・世界の疼痛管理治療市場規模：流通チャネル別 - 小売薬局の市場規模 - オンライン薬局の市場規模 - その他流通チャネルの市場規模 ・世界の疼痛管理治療市場規模：地域別 - 北米の疼痛管理治療市場規模 - ヨーロッパの疼痛管理治療市場規模 - アジア太平洋の疼痛管理治療市場規模 - 中南米の疼痛管理治療市場規模 - 中東/アフリカの疼痛管理治療市場規模 ・競争状況 ・企業情報 |
Pain Management Therapeutics Market – Scope of Report
TMR’s report on the global pain management therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global pain management therapeutics market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global pain management therapeutics market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the pain management therapeutics market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global pain management therapeutics market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global pain management therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global pain management therapeutics market.
The report delves into the competitive landscape of the global pain management therapeutics market. Key players operating in the global pain management therapeutics market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global pain management therapeutics market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market pain management therapeutics.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Pain Management Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Therapeutics Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Pain Management Therapeutics Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Mergers & Acquisitions
5.3. Covid 19 Impact Analysis
6. Global Pain Management Therapeutics Market Analysis and Forecast, by Therapeutic
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Therapeutic, 2017–2031
6.3.1. Anticonvulsants
6.3.2. Antidepressants
6.3.3. Anesthetics
6.3.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
6.3.5. Opioids
6.3.6. Other Non-narcotic Analgesic
6.3.7. Antimigraine Agents
6.4. Market Attractiveness Analysis, by Therapeutic
7. Global Pain Management Therapeutics Market Analysis and Forecast, by Indication
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Indication, 2017–2031
7.3.1. Neuropathic Pain
7.3.2. Fibromyalgia
7.3.3. Arthritic Pain
7.3.4. Chronic Back Pain
7.3.5. Migraine
7.3.6. Post-operative Pain
7.3.7. Cancer Pain
7.4. Market Attractiveness Analysis, by Indication
8. Global Pain Management Therapeutics Market Analysis and Forecast, by Route of Administration
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Route of Administration, 2017–2031
8.3.1. Oral
8.3.2. Parenteral
8.3.3. Others
8.4. Market Attractiveness Analysis, by Route of Administration
9. Global Pain Management Therapeutics Market Analysis and Forecast, by Distribution Channel
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Distribution Channel, 2017–2031
9.3.1. Retail Pharmacies
9.3.2. Online Pharmacies
9.3.3. Others
9.4. Market Attractiveness Analysis, by Distribution Channel
10. Global Pain Management Therapeutics Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, by Region
11. North America Pain Management Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Therapeutic, 2017–2031
11.2.1. Anticonvulsants
11.2.2. Antidepressants
11.2.3. Anesthetics
11.2.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
11.2.5. Opioids
11.2.6. Other Non-narcotic Analgesic
11.2.7. Antimigraine Agents
11.3. Market Value Forecast, by Indication, 2017–2031
11.3.1. Neuropathic Pain
11.3.2. Fibromyalgia
11.3.3. Arthritic Pain
11.3.4. Chronic Back Pain
11.3.5. Migraine
11.3.6. Post-operative Pain
11.3.7. Cancer Pain
11.4. Market Value Forecast, by Route of Administration, 2017–2031
11.4.1. Oral
11.4.2. Parenteral
11.4.3. Others
11.5. Market Value Forecast, by Distribution Channel, 2017–2031
11.5.1. Retail Pharmacies
11.5.2. Online Pharmacies
11.5.3. Others
11.6. Market Value Forecast, by Country, 2017–2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Therapeutic
11.7.2. By Indication
11.7.3. By Route of Administration
11.7.4. By Distribution Channel
11.7.5. By Country
12. Europe Pain Management Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Therapeutic, 2017–2031
12.2.1. Anticonvulsants
12.2.2. Antidepressants
12.2.3. Anesthetics
12.2.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
12.2.5. Opioids
12.2.6. Other Non-narcotic Analgesic
12.2.7. Antimigraine Agents
12.3. Market Value Forecast, by Indication, 2017–2031
12.3.1. Neuropathic Pain
12.3.2. Fibromyalgia
12.3.3. Arthritic Pain
12.3.4. Chronic Back Pain
12.3.5. Migraine
12.3.6. Post-operative Pain
12.3.7. Cancer Pain
12.4. Market Value Forecast, by Route of Administration, 2017–2031
12.4.1. Oral
12.4.2. Parenteral
12.4.3. Others
12.5. Market Value Forecast, by Distribution Channel, 2017–2031
12.5.1. Retail Pharmacies
12.5.2. Online Pharmacies
12.5.3. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Therapeutic
12.7.2. By Indication
12.7.3. By Route of Administration
12.7.4. By Distribution Channel
12.7.5. By Country/Sub-region
13. Asia Pacific Pain Management Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Therapeutic, 2017–2031
13.2.1. Anticonvulsants
13.2.2. Antidepressants
13.2.3. Anesthetics
13.2.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
13.2.5. Opioids
13.2.6. Other Non-narcotic Analgesic
13.2.7. Antimigraine Agents
13.3. Market Value Forecast, by Indication, 2017–2031
13.3.1. Neuropathic Pain
13.3.2. Fibromyalgia
13.3.3. Arthritic Pain
13.3.4. Chronic Back Pain
13.3.5. Migraine
13.3.6. Post-operative Pain
13.3.7. Cancer Pain
13.4. Market Value Forecast, by Route of Administration, 2017–2031
13.4.1. Oral
13.4.2. Parenteral
13.4.3. Others
13.5. Market Value Forecast, by Distribution Channel, 2017–2031
13.5.1. Retail Pharmacies
13.5.2. Online Pharmacies
13.5.3. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Therapeutic
13.7.2. By Indication
13.7.3. By Route of Administration
13.7.4. By Distribution Channel
13.7.5. By Country/Sub-region
14. Latin America Pain Management Therapeutics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Therapeutic, 2017–2031
14.2.1. Anticonvulsants
14.2.2. Antidepressants
14.2.3. Anesthetics
14.2.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
14.2.5. Opioids
14.2.6. Other Non-narcotic Analgesic
14.2.7. Antimigraine Agents
14.3. Market Value Forecast, by Indication, 2017–2031
14.3.1. Neuropathic Pain
14.3.2. Fibromyalgia
14.3.3. Arthritic Pain
14.3.4. Chronic Back Pain
14.3.5. Migraine
14.3.6. Post-operative Pain
14.3.7. Cancer Pain
14.4. Market Value Forecast, by Route of Administration, 2017–2031
14.4.1. Oral
14.4.2. Parenteral
14.4.3. Others
14.5. Market Value Forecast, by Distribution Channel, 2017–2031
14.5.1. Retail Pharmacies
14.5.2. Online Pharmacies
14.5.3. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Therapeutic
14.7.2. By Indication
14.7.3. By Route of Administration
14.7.4. By Distribution Channel
14.7.5. By Country/Sub-region
15. Middle East & Africa Pain Management Therapeutics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Therapeutic, 2017–2031
15.2.1. Anticonvulsants
15.2.2. Antidepressants
15.2.3. Anesthetics
15.2.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
15.2.5. Opioids
15.2.6. Other Non-narcotic Analgesic
15.2.7. Antimigraine Agents
15.3. Market Value Forecast, by Indication, 2017–2031
15.3.1. Neuropathic Pain
15.3.2. Fibromyalgia
15.3.3. Arthritic Pain
15.3.4. Chronic Back Pain
15.3.5. Migraine
15.3.6. Post-operative Pain
15.3.7. Cancer Pain
15.4. Market Value Forecast, by Route of Administration, 2017–2031
15.4.1. Oral
15.4.2. Parenteral
15.4.3. Others
15.5. Market Value Forecast, by Distribution Channel, 2017–2031
15.5.1. Retail Pharmacies
15.5.2. Online Pharmacies
15.5.3. Others
15.6. Market Value Forecast, by Country/Sub-region, 2017–2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Therapeutic
15.7.2. By Indication
15.7.3. By Route of Administration
15.7.4. By Distribution Channel
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (by tier and size of companies)
16.2. Market Share Analysis, by Company, 2021
16.3. Company Profiles
16.3.1. Abbott Laboratories
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Financial Analysis
16.3.1.3. Growth Strategies
16.3.1.4. SWOT Analysis
16.3.2. AstraZeneca plc
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Financial Analysis
16.3.2.3. Growth Strategies
16.3.2.4. SWOT Analysis
16.3.3. Pfizer, Inc.
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Financial Analysis
16.3.3.3. Growth Strategies
16.3.3.4. SWOT Analysis
16.3.4. Depomed, Inc.
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Financial Analysis
16.3.4.3. Growth Strategies
16.3.4.4. SWOT Analysis
16.3.5. Endo International plc
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Financial Analysis
16.3.5.3. Growth Strategies
16.3.5.4. SWOT Analysis
16.3.6. GlaxoSmithKline plc
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Financial Analysis